FDA Blocked From Approving More Norvasc Generics Until At Least April 13
Mylan has at least three weeks to market its generic version of Norvasc (amlodipine besylate) before FDA can approve additional generics, based on a federal court decision to grant Mylan's request for a temporary restraining order enjoining FDA from issuing ANDA approvals for the generic hypertension drug
You may also be interested in...
US FDA final guidance describes possible study design to test whether selected names may misbrand a drug. Agency also okays use of two-letter USAN stems in product names and clarifies use of modifiers.
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.